Dataset Information

Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?

ABSTRACT: For the first 3 months of COVID-19 pandemic, COVID-19 was expected to be an immunizing non-relapsing disease. We report a national case series of 11 virologically-confirmed COVID-19 patients having experienced a second clinically- and virologically-confirmed acute COVID-19 episode. According to the clinical history, we discuss either re-infection or reactivation hypothesis. Larger studies including further virological, immunological and epidemiologic data are needed to understand the mechanisms of these recurrences.

SUBMITTER: Gousseff M

PROVIDER: S-EPMC7326402 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?

Gousseff Marie M Penot Pauline P Gallay Laure L Batisse Dominique D Benech Nicolas N Bouiller Kevin K Collarino Rocco R Conrad Anne A Slama Dorsaf D Joseph Cédric C Lemaignen Adrien A Lescure François-Xavier FX Levy Bruno B Mahevas Matthieu M Pozzetto Bruno B Vignier Nicolas N Wyplosz Benjamin B Salmon Dominique D Goehringer Francois F Botelho-Nevers Elisabeth E

The Journal of infection 20200630 5

For the first 3 months of COVID-19 pandemic, COVID-19 was expected to be an immunizing non-relapsing disease. We report a national case series of 11 virologically-confirmed COVID-19 patients having experienced a second clinically- and virologically-confirmed acute COVID-19 episode. According to the clinical history, we discuss either re-infection or reactivation hypothesis. Larger studies including further virological, immunological and epidemiologic data are needed to understand the mechanisms ...[more]

PMID: 32619697

Similar Datasets

Project description:ImportanceThe benefit of vaccination for preventing reinfection among individuals who have been previously infected with SARS-CoV-2 is largely unknown.ObjectiveTo obtain population-based estimates of the probability of SARS-CoV-2 reinfection and the effectiveness associated with vaccination after recovery from COVID-19.Design, setting, and participantsThis cohort study used Rhode Island statewide surveillance data from March 1, 2020, to December 9, 2021, on COVID-19 vaccinations, laboratory-confirmed cases, hospitalizations, and fatalities to conduct a population-based, retrospective study during periods when wild type, Alpha, and Delta strains of SARS-CoV-2 were predominant. Participants included Rhode Island residents aged 12 years and older who were previously diagnosed with COVID-19 and unvaccinated at the time of first infection, stratified into 3 subpopulations: long-term congregate care (LTCC) residents, LTCC employees, and the general population (ie, individuals not associated with congregate settings). Data were analyzed from October 2021 to January 2022.ExposuresCompletion of the primary vaccination series, defined as 14 days after the second dose of an mRNA vaccine or 1 dose of vector virus vaccine.Main outcomes and measuresThe main outcome was SARS-CoV-2 reinfection, defined as a laboratory-confirmed positive result on a polymerase chain reaction (PCR) or antigen test at least 90 days after the first laboratory-confirmed positive result on a PCR or antigen test.ResultsOverall, 3124 LTCC residents (median [IQR] age, 81 [71-89]; 1675 [53.6%] females), 2877 LTCC employees (median [IQR] age, 41 [30-53]; 2186 [76.0%] females), and 94 516 members of the general population (median [IQR] age, 35 [24-52] years; 45 030 [47.6%] females) met eligibility criteria. Probability of reinfection at 9 months for those who remained unvaccinated after recovery from prior COVID-19 was 13.0% (95% CI, 12.0%-14.0%) among LTCC residents, 10.0% (95% CI, 8.8%-11.5%) among LTCC employees, and 1.9% (95% CI, 1.8%-2.0%) among the general population. Completion of the primary vaccination series after infection was associated with 49% (95% CI, 27%-65%) protection among LTCC residents, 47% (95% CI, 19%-65%) protection among LTCC employees, and 62% (95% CI, 56%-68%) protection in the general population against reinfection, adjusting for potential sociodemographic and clinical confounders and temporal variation in infection rates.Conclusions and relevanceThese findings suggest that risk of SARS-CoV-2 reinfection after recovery from COVID-19 was relatively high among individuals who remained unvaccinated. Vaccination after recovery from COVID-19 was associated with reducing risk of reinfection by approximately half.

Project description:Although COVID-19 lockdown policies have improved air quality in numerous countries, there is a lack of empirical evidence on the extent to which recovery has resulted in air pollution rebound, and the differences and similarities among regions' recovery modes during the period of easing COVID-19 restrictions. Here, we used daily air quality data and the recovery index constructed by a city-pair inflow index for 119 cities in China to quantify the impact of recovery on air pollution from March 2 to October 30, 2020. Findings show that recovery has significantly increased air pollution. When the recovery level increased by 10 %, the concentration of PM2.5, SO2, and NO2 respectively deteriorated by 1.10, 0.33, 1.25 μg/m3, and the average growth rates of three air pollutants were about 3 %-6 %. Moreover, we used the counterfactual framework and time series clustering with wavelet transform to cluster the rebound trajectory of air pollution for 17 provinces into five recovery modes. Results show that COVID-19 has further intensified regional differentiations in economic development ability and green recovery trend. Three northwestern provinces dependent on their resource endowments belong to energy-intensive recovery mode, which have experienced a sharp rebound of air pollution for two months, thereby making green recovery more challenging to achieve. Three regions with a diversified industrial structure are in industrial-restructuring recovery mode, which has effectively returned to a normal level through adjusting industrial structure and technological innovation. Owing to local policies and the outbreak of COVID-19 in other countries, six provinces in policy-oriented and international trade-oriented recovery modes have not fully recovered to the level without COVID-19 until October 2020. The result highlights the importance of diversifying industrial structure, technological innovation, policy flexibility and industrial upgrading for different recovery modes to achieve long-term green recovery in the future.

Dataset Information

Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?

Publications

Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection or inflammatory rebound?

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets